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To the Editor: We read with great interest the 
Matsumura et al. paper describing extended-spectrum 
β-lactamase (ESBL) CTX-M-27–producing Escherichia 
coli of sequence type (ST) 131 clonal group, an emerging 
clade called C1-M27 (1). ST131 E. coli having bla
CTX-M-27
 
has been described in several countries. We observed an 
alarming increase of this clonal group in the fecal carriage 
of children in France (0% in 2010 to 65% in 2015 among 
ESBL-producing ST131 E. coli) (2). 
We wondered whether this clonal group’s expansion 
in France was attributable to the same clade (C1-M27). For 
that, we designed primers (M27PP1-B-F, 5′-TTACTCC-
GACTATGCGTTCAC-3′; M27PP1-B-R, 5′-CAAACTT-
GCCCCTGATAGCG-3′; amplicon length, 1.5 kb) to amplify 
the insertion site of the structure comprising the direct repeat 
and prophage-like genomic island of E. coli PCN033, as pre-
viously described (1). PCR was performed on our recently 
described collection of 39 ESBL-producing ST131 E. coli, 
including 16 CTX-M-27–producing E. coli: 13 of subgroup 
O25b with fimH30 allele and 3 of O16 subgroup with fimH41 
allele (2). Results showed that 81% (13/16) of the CTX-M-27–
producing E. coli ST131 had the M27PP1 structure, similar to 
strain PCN033, and thus belong to the C1-M27 clade. There-
fore, the C1-M27 clade found in Asia and America is also 
present in Europe in the fecal flora of young children. The 3 
isolates belonging to the O16 subgroup with fimH41 lacked 
M27PP1, suggesting that bla
CTX-M-27
 might diffuse among non-
H30 ST131 E. coli without this prophage-like genomic island. 
Finally, the non–CTX-M-27–producing ST131 E. coli of our 
collection were negative for M27PP1 elements.
Our results show that CTX-M-27–producing E. coli 
ST131 subgroup O25b with fimH30 allele (one third of the 
ESBL-producing ST131 carriage isolates) isolated from 
children in France belong to C1-M27 and that CTX-M-27–
producing O16 strains display distinct genetic characteris-
tics. Altogether, our data confirm the worldwide distribution 
of C1-M27 and its high prevalence in children in France.
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To the Editor: The Kassem et al. article regarding 
high rates of multidrug-resistant (MDR) bacteria coloniz-
ing Syrian children highlights the challenge of choosing 
empiric antimicrobial drugs to treat war-injured refugees 
from Syria (1). The findings mirror other reports (2,3) and 
our own experience in a charitable hospital in Amman, 
Jordan, which manages war-injured refugees from Syria. 
As part of a program of antimicrobial drug stewardship 
and infection prevention and control, empiric antimicro-
bial drug protocols were introduced. For antimicrobial 
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